Across 164 European haematology Phase III trials authorized through CTIS from 2024–2026, 96 trials used at least one CTIS-listed CRO or outsourced support provider, equal to 58.5% of the cohort. ICON Clinical Research was the most active named provider, appearing in 27/164 trials, followed by IQVIA in 20/164 and Parexel in 16/164. CRO demand was strongest in operationally complex EU submissions: 50/52 trials with 7+ countries used CRO support, compared with only 6/48 one-country trials.
ICON Clinical Research led the CTIS-listed support landscape with 27/164 trials, representing 16.5% of all haematology Phase III trials and 28.1% of CRO-supported trials. IQVIA followed with 20/164 trials, Parexel with 16/164, and PPD / Thermo Fisher with 14/164.
| Provider | Trials | All trials | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| ICON Clinical Research | 27 | 16.5% | 18 | 7 | 2 |
| IQVIA | 20 | 12.2% | 16 | 3 | 1 |
| Parexel | 16 | 9.8% | 10 | 3 | 3 |
| PPD / Thermo Fisher | 14 | 8.5% | 12 | 1 | 1 |
| Syneos Health | 11 | 6.7% | 10 | 1 | 0 |
| Medidata | 11 | 6.7% | 9 | 2 | 0 |
| Endpoint Clinical Inc. | 10 | 6.1% | 6 | 3 | 1 |
| Almac Clinical Services Limited | 9 | 5.5% | 6 | 2 | 1 |
The ranking is led by full-service CROs, but the top group also includes specialist vendors for data capture, randomisation, and logistics. For CTIS-facing EU haematology programs, outsourcing is therefore not only trial management; it is a bundled operating model spanning country activation, site operations, data systems, and supply controls.
Country footprint was the strongest CRO trigger. CRO support appeared in 80/88 trials with 4+ European countries, equal to 90.9%, and in 50/52 trials with 7+ countries, equal to 96.2%. Site count was a weaker but still relevant signal: 43/64 trials with 26+ sites used CRO support, equal to 67.2%.
In European haematology Phase III trials, CRO need is more strongly tied to EU country complexity than to participant volume. The 7+ country threshold is the clearest outsourcing trigger, because it combines CTIS Part II country coordination, local site start-up, language-specific consent materials, and multi-country operational governance.
Among disease groups with at least five trials, paroxysmal nocturnal hemoglobinuria had the highest CRO-support rate at 7/7 trials, equal to 100.0%. Hemophilia followed at 9/11 trials, or 81.8%, and thrombosis/coagulation studies reached 11/15 trials, or 73.3%.
| Disease group | CRO trials | Total | Rate |
|---|---|---|---|
| Paroxysmal nocturnal hemoglobinuria | 7 | 7 | 100.0% |
| Hemophilia | 9 | 11 | 81.8% |
| Thrombosis / coagulation | 11 | 15 | 73.3% |
| Anemia / red-cell disorders | 6 | 9 | 66.7% |
| Multiple myeloma | 11 | 19 | 57.9% |
| Myelodysplastic syndrome | 5 | 9 | 55.6% |
| Sickle cell disease | 7 | 13 | 53.8% |
| Lymphoma | 7 | 22 | 31.8% |
The strongest CRO need appears in rare or operationally specialized haematology segments rather than only in the largest oncology-haematology malignancy categories. PNH and hemophilia combine small participant pools with multi-country site networks, making CRO support valuable for feasibility, patient access, CTIS country coordination, and specialist site activation.
The most common outsourced functions were central lab/biomarker testing in 94/164 trials, equal to 57.3%, and full-service CRO or clinical operations in 93/164 trials, equal to 56.7%. Digital data capture, electronic clinical outcome assessment (eCOA), and electronic trial master file (eTMF) support appeared in 67/164 trials, equal to 40.9%.
The outsourced stack is heavily operational and infrastructure-led. In haematology Phase III, sponsors most often need partners for laboratory and biomarker workflows, EU site operations, digital data capture, RTSM, IMP logistics, safety review, imaging, and patient-support services rather than only generic monitoring.
The dataset included 803 country-trial submission records across 25 European countries. Italy, France, Spain, Germany, and Poland formed the largest CRO-supported CTIS execution footprint: Italy had 78 CRO-supported country-trial records, France 73, Spain 73, Germany 60, and Poland 57.
| Country | Trial records | CRO records | CRO rate | Sites | Participants |
|---|---|---|---|---|---|
| Italy | 96 | 78 | 81.2% | 810 | 6,077 |
| France | 99 | 73 | 73.7% | 1,029 | 11,010 |
| Spain | 87 | 73 | 83.9% | 544 | 2,893 |
| Germany | 83 | 60 | 72.3% | 607 | 6,247 |
| Poland | 60 | 57 | 95.0% | 240 | 1,177 |
| Greece | 41 | 41 | 100.0% | 117 | 652 |
The highest CRO workload sits in recurring EU5 and Central/Eastern European activation corridors. Italy, France, Spain, Germany, and Poland account for much of the country-level CTIS operating burden, especially when sponsors need local document handling, site start-up, feasibility, and country-specific implementation after EU submission.
The strongest adjacent CRO-demand signals were orphan status, paediatric inclusion, digital recruitment, and advanced therapy modality. Orphan haematology trials used CRO support in 46/57 trials, equal to 80.7%, while paediatric trials used CRO support in 37/50 trials, equal to 74.0%.
The clearest adjacent commercial targets are rare-disease haematology, paediatric haematology, digitally supported recruitment models, and gene-therapy programs. These trial types increase dependence on specialist feasibility, patient access, consent localization, vendor coordination, and CTIS country execution.
The European haematology Phase III market is not uniformly CRO-dependent. The clearest CRO need emerges when trials cross the 4-country CTIS threshold, enter 7+ country execution, involve orphan or paediatric populations, or require specialized lab, digital, supply, safety, and patient-support vendors.